International application No.

	· · · · · · · · · · · · · · · · · · ·	PCT	/JP2004/014935
A. CLASSIF Int.Cl	CATION OF SUBJECT MATTER C07K16/00, A61K9/08, 39/395,	47/02, 47/18, 47/2	6, A61P35/00
	nternational Patent Classification (IPC) or to both nation	nal classification and IPC	
B. FIELDS S			
Minimum docu Int.Cl	mentation searched (classification system followed by 6.7 C07K16/00, A61K9/08, 39/395,	classification symbols) 47/02, 47/18, 47/2	6, A61P35/00
Documentation	searched other than minimum documentation to the ext	ent that such documents are include	ed in the fields searched
Electronic data MEDLIN	base consulted during the international search (name of E (SNT), BIOSIS (STN), WPIDS (STN	data base and, where practicable, s), JICST FILE (JOIS)	search terms used)
C. DOCUME	NTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where a	ppropriate, of the relevant passages	Relevant to claim No.
X A	JP 2001-504092 A (Rotkreuzst Zentrallaboratorium Blutspend 27 March, 2001 (27.03.01), Claims; examples & EP 835880 A1 & WC & US 6136312 A1	ifung dedienst SRK), 98/16558 Al	1-4,9 10,11
X A	JP 9-127114 A (Dainabot Co., 16 May, 1997 (16.05.97), Claims; example 1; Fig. 1 (Family: none)	Ltd.),	1-3,9,10 4,11
X A	JP 9-127112 A (Dainabot Co., 16 May, 1997 (16.05.97), Claims; example 1; Fig. 1 (Family: none)	Ltd.),	1-3,9-11
× Further do	cuments are listed in the continuation of Box C.	See patent family annex.	
Special cate 'A" document de to be of part 'E" earlier applie	gories of cited documents: efining the general state of the art which is not considered icular relevance cation or patent but published on or after the international	"T" later document published after date and not in conflict with the the principle or theory underlyi document of particular relevant	ce; the claimed invention cannot be
'L" document w cited to esta special reaso	filing date " document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) considered novel step when the doc document of participants considered to in		c considered to involve an inventive an alone ce; the claimed invention cannot be entive step when the document is
	ferring to an oral disclosure, use, exhibition or other means iblished prior to the international filing date but later than the claimed	combined with one or more oth being obvious to a person skille "&" document member of the same	
	completion of the international search tary, 2005 (04.01.05)	Date of mailing of the internation 25 January, 200	nal search report 5 (25.01.05)
	g address of the ISA/ se Patent Office	Authorized officer	
rm PCT/ISA/21	0 (second sheet) (January 2004)	Telephone No.	

International application No.

PCT/JP2004/014935

		PC1/UP2C	04/014935
C (Continuation)	DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relev	ant passages	Relevant to claim No.
X A	JP 2-786335 A (Biotest Wolfram), 19 March, 1990 (19.03.90), Claims; page 3, upper left column; exampl & EP 352500 A & US 5190752 A	Les	1-4,9 10,11
X A	<pre>JP 2-493 A (Miles Inc.), 05 January, 1990 (05.01.90), Claims; examples; page 5, upper right col & EP 303088 A & US 5157113 A</pre>	Lumn	1-4,9,10
х	GOMBOTZ WR et al., "The stabilization of human IgM monoclonal antibody with poly (vinylpyrrolidone)." Pharm Res., 1994, Vol.11, No.5, page 624-32	a	1-4,9-11
А	DRABER P. et al., "Stability of monoclonary IgM antibodies freeze-dried in the present of trehalose." J Immunol Methods., 1995, Vol.181, No.1, pages 37 to 43		1-4,9-11
		*	
		:	
·			

International application No.
PCT/JP2004/014935

ntinuation of item 2 of first sheet)
der Article 17(2)(a) for the following reasons:
de America
hading namely:
thority, namely:
\
ply with the prescribed requirement
ply with the prescribed requirements to such an ally:
`
an 1-64(a)
th the second and third sentences of Rule 0.4(2).
th the second and third sentences of Rule 6.4(a).
tion of items
tional application, as follows: tabilization of an IgM solution P 2001-504092 A (Rotkreuzstifung A March, 2001 (27.03.01))
P 2001-504092 A (Rotkreuzstifung 27 March, 2001 (27.03.01)) 27 March, and thus, it igh concentration, and document
2001 March. 2001 (27.03.11)
27 Martion, and thus, 25
igh concentration, and thus, it igh concentration, and document er is disclosed in said document er is disclosed in said document.
igh concentration, and thus, it igh concentration and thus, it is disclosed in said document er is disclosed in said document stabilization of an IgM solution stabilization art, and therefore,
igh concentration, and thus, it igh concentration, and thus, it is disclosed in said document er is disclosed in said document stabilization of an IgM solution e of the prior art, and therefore, nical feature. Accordingly, the nical feature extra sheet)
nical feature. According
(continued to exceed all searchable
e of the pitot. Accordingly, the nical feature. Accordingly, the (continued to extra sheet) ant, this international search report covers all searchable additional fee, this Authority did not invite payment of
additional fee, this Authority did not invite payment of
l addition
additional fee, this Authority did not invite payment of id by the applicant, this international search report covers os.:
os.:
Consequently, this international search report is
Consequently, this international search report is
Consequently, this international search report is
licant. Consequently, this international search report is vered by claims Nos.:
licant. Consequently, this international search report is vered by claims Nos.:
licant. Consequently, this international search report is vered by claims Nos.:
licant. Consequently, this international search report is vered by claims Nos.:
licant. Consequently, this international search report is vered by claims Nos.:

International application No.

PCT/JP2004/014935

Continuation of Box No.III of continuation of first sheet(2)

are classified into a group of inventions according to claims 1 to 4 and 9 to 11 relating to a solution containing a stabilized immunoglobulin at a high concentration, wherein the immunoglobulin is IgM, a group of inventions according to claims 5 to 8, 13 to 22, 24 to 34 having a technical feature of a high concentration IgM solution containing a multi-valent cationic ion, and a group of inventions according to claims 12, 23 and 35 having a technical feature of the freezing or freeze-drying of a stabilized IgM solution of a high concentration.